A Two-Part Intervention to Target Cardiovascular Health
Autism Research Consortium on Physical Health: A Two-Part Intervention to Target Cardiovascular Health
Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals. This places them at heightened risk for cardiovascular disease (CVD) and mortality before they enter adulthood. Studies have identified three key contributing factors to CVD outcomes in autistic individuals: unhealthy lifestyle behaviors, Adverse Childhood Experiences (ACEs), and chronic stress.
This study will explore the effectiveness of two CVD-focused primary care interventions for autistic individuals (ages 9-26): (1) lifestyle medicine consultations tailored towards supporting health-promoting behaviors; and (2) a Cognitive Behavioral Therapy (CBT) intervention tailored towards addressing chronic stress that contributes to excess weight and maladaptive eating behaviors and results in obesity and CVD. Participants and their caregivers will be randomly placed into either the Lifestyle Medicine Group, CBT Group, or combined Lifestyle Medicine with CBT Group. Participants will respond to questionnaires and surveys measuring lifestyle habits, stress, and psychological risk factors at their first visit, 6-month visit, and 3 months post-intervention visit. Over the course of 6 months, participants will attend virtual sessions (up to three times a month) in accordance with their intervention group.
Aperçu de l'étude
Statut
Description détaillée
Autistic individuals experience almost three times the mortality rate relative to non-autistic populations, and are disproportionately likely to experience obesity-with increasing rates beginning in childhood and adolescence-relative to both the general population and those with other developmental conditions. Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals. This places them at heightened risk for cardiovascular disease (CVD) and mortality before they enter adulthood.
Studies have identified three key contributing factors to CVD outcomes in autistic individuals: unhealthy lifestyle behaviors, Adverse Childhood Experiences (ACEs), and chronic stress. Taken together, this study addresses a critical gap in the field: lack of appropriate and effective healthcare/lifestyle interventions for autistic individuals with CVD and/or experiences of chronic stress that lead to obesity and poor cardiovascular health. These efforts require dedicated interventions selected for their impact on two key mechanisms underlying obesity and CVD: lifestyle and ACEs/chronic stress.
This study will explore the effectiveness of two CVD-focused primary care interventions for autistic individuals (ages 9-26): (1) lifestyle medicine consultations tailored towards supporting health-promoting behaviors; and (2) a Cognitive Behavioral Therapy (CBT) intervention tailored towards addressing chronic stress that contributes to excess weight and maladaptive eating behaviors and results in obesity and CVD. Participants and their caregivers will be randomly placed into either the Lifestyle Medicine Group, CBT Group, or combined Lifestyle Medicine with CBT Group. Participants will respond to questionnaires and surveys measuring lifestyle habits, stress, and psychological risk factors at their first visit, 6-month visit, and 3 months post-intervention visit. Over the course of 6 months, participants will attend virtual sessions (up to three times a month) in accordance with their intervention group.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90024
- 1100 Glendon Ave
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
• Have a diagnosis of autism or be told by a healthcare provider that you have autism
- Be between the ages of 9 and 26
- Have a BMI greater than the 84th percentile
- English speaking
Exclusion Criteria:
• Children younger than 9 years of age
- Adults older than 26 years of age
- Individuals without a diagnosis of autism
- Individuals with a BMI less than the 84th percentile
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 1) Lifestyle Medicine Group
This group will receive the Lifestyle Medicine Intervention.
This intervention is comprised of 6 monthly lifestyle medicine consultations with a health coach.
|
The intervention is a series of lifestyle medicine consultations.
|
|
Comparateur actif: Cognitive Behavioral Therapy (CBT) Group
This group will receive the CBT Intervention.
This intervention is comprised of 12, twice-monthly CBT sessions over the span of 6 months.
|
The intervention is a series of CBT sessions.
|
|
Comparateur actif: Lifestyle Medicine with CBT Group
This group will receive both the Lifestyle Medicine and CBT Interventions.
|
Receives both Lifestyle Medicine and CBT interventions
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Behavior Assessment System for Children: Third Edition (BASC-3)
Délai: Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
A series of instruments designed to help aid in the diagnosis and treatment of children, adolescents, and young adults between the ages of 2 and 25 - captures self- and/or caregiver reported psychological distress.
|
Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
American College of Lifestyle Medicine (ACLM) Nutrition in Action Diet Screener
Délai: Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Self- and/or caregiver reported diet, physical activity, sleep, stress, and motivation to change.
|
Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
Adverse Childhood Experiences Screener (PEARLS/ACEs)
Délai: Administered at Baseline
|
Captures adverse childhood experiences.
|
Administered at Baseline
|
|
General Nutrition Knowledge Questionnaire (GNKQ)
Délai: Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Captures general knowledge of nutrition and food groups.
|
Administered at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
Project EAT-IV Survey
Délai: Administered at Baseline
|
Self- and/or caregiver reported diet, physical activity, sleep, and stress.
|
Administered at Baseline
|
|
Participant and Caregiver Survey
Délai: Administered at final intervention visit (6-month mark).
|
Addresses participant and caregiver experience in the study - captures acceptability and feasibility of intervention.
|
Administered at final intervention visit (6-month mark).
|
|
Childhood Autism Rating Scale: Second Edition (CARS-2)
Délai: Administered at Baseline
|
Identifies autism spectrum disorder (ASD) in children and the severity of their symptoms.
|
Administered at Baseline
|
|
ASD DSM-5 Checklist
Délai: Administered at Baseline
|
Captures diagnostic criterion from clinicians when used to diagnose Autism Spectrum Disorder.
|
Administered at Baseline
|
|
Vineland Adaptive Behavioral Scales: Third Edition (Vineland-III)
Délai: Administered at Baseline
|
Used to measure adaptive behaviors and aid in the diagnosis of intellectual and developmental disabilities.
|
Administered at Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cardiovascular disease (CVD) indicators
Délai: Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Height (cm)
|
Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
Cardiovascular disease (CVD) indicators
Délai: Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Weight (kg)
|
Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
Cardiovascular disease (CVD) indicators
Délai: Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Waist circumference (cm)
|
Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
|
Cardiovascular disease (CVD) indicators
Délai: Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Blood pressure (mmHg)
|
Collected at Baseline, at final intervention visit (6-month mark), and 3-Months post-intervention.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Alice Kuo, MD, PhD, University of California, Los Angeles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 25-1848
- 6 UM4MC54990-01-01 (Autre subvention/numéro de financement: HRSA)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .